NCT05213481View on ClinicalTrials.gov

Tepotinib Drug-Drug Interaction Study With Carbamazepine in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

December 15, 2021

Primary Completion Date

May 6, 2022

Study Completion Date

May 6, 2022

Conditions
Healthy
Interventions
DRUG

Tepotinib

Participants received Tepotinib hydrochloride hydrate film-coated tablet once daily with food on Day 1 and Day 26 in the morning.

DRUG

Carbamazepine

Carbamazepine 100 mg twice daily at Day 8 and 9, 200 mg twice daily at Day 10 and 11, 300 mg twice daily from Day 12 to 32.

Trial Locations (1)

Unknown

Nuvisan GmbH, Neu-Ulm

All Listed Sponsors
lead

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

INDUSTRY

NCT05213481 - Tepotinib Drug-Drug Interaction Study With Carbamazepine in Healthy Participants | Biotech Hunter | Biotech Hunter